ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1650926
Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism
Provisionally accepted
- 1Mira Pharmaceuticals, Inc., #1183 Miami, Florida 33133, United States
- 2Pharmaseed Ltd., Nes-Ziona, Israel
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Ketamir-2 is a novel ketamine analog with improved oral bioavailability and superior safety profile compared to existing ketamine treatments of pain. It is a low affinity NMDA receptor antagonist, that selectively binds to the PCP-site.Ketamir-2 was evaluated in two pharmacological models of neuropathic pain in rats and mice to evaluate its potential in this disease. These tests included the Chung spinal nerve ligation model in rats and in mechanical allodynia and thermal hyperalgesia in paclitaxel (PTX)-induced neuropathy in mice. Ketamir-2, administered orally as the pamoate salt has shown significant effects in both tests at variable doses. In these models, it was more effective than orally administered ketamine, pregabalin or gabapentin, which were used as a positive control.
Keywords: Ketamine, Ketamir-2, allodynia, NMDA, neuropathic pain, Von-frey, Paclitaxel
Received: 20 Jun 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Angel, Perelroizen, Pichinuk and Aminov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Itzchak Angel, Mira Pharmaceuticals, Inc., #1183 Miami, Florida 33133, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.